Form 8-K · Current report
McKesson Corporation 8-K, filed Aug 5, 2026
- Filed
- CIK
- 0000927653
- Accession no.
- 0000927653-26-000232
Summary
McKesson reported fiscal 2027 first-quarter revenue of $105.4 billion, up 8% from a year earlier, with GAAP earnings per diluted share of $5.15 (down $1.10) and adjusted earnings per diluted share of $9.93 (up 20%), and raised its full-year adjusted EPS guidance to $44.20–$45.00 from $43.80–$44.60. The company also approved a 15% dividend increase to $0.94 per share, progressed its planned separation of the Medical-Surgical Solutions segment — selling a roughly 13% minority stake to Apollo Funds for $1.25 billion and naming the future standalone business Wellverse — and reported that Thomas L. Rodgers retired as chief strategy and business development officer, succeeded by Ramesh Srinivasan.
Key points
- McKesson's board approved a 15% quarterly dividend increase to $0.94 per share, the tenth consecutive year of increases, and the company returned $2.6 billion to shareholders in the quarter, including $2.25 billion under an accelerated share repurchase program.
- McKesson sold an approximately 13% minority interest in its Medical-Surgical Solutions business to Apollo Funds for $1.25 billion and established a $2.25 billion Term Loan B facility supporting the planned separation of that segment.
- McKesson named Wellverse as the future standalone Medical-Surgical Solutions business.
- Thomas L. Rodgers retired as Executive Vice President, Chief Strategy and Business Development Officer effective August 1, 2026, with Ramesh Srinivasan assuming the role of Executive Vice President and Chief Strategy Officer.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition. On August 5, 2026, McKesson Corporation (the “Company”) reported the Company’s preliminary results for the quarter ended on June 30, 2026 which are attached hereto as Exhibit 99.1. The information contained in this Form 8-K, including Exhibit 99.1, is furnished to the Securities and Exchange Commission (the “Commission”), but shall not be deemed “filed” with the Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific…
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.